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Abstract. 
Hepatocellular carcinoma (HCC) with heart involvement is uncommon. Herein, we report 
a 58-year-old male with advanced HCC and right atrium involvement. The patient’s HCC was 
detected accidentally by routine image follow-up because he lacked typical signs of right heart 
failure and had not suffered any thromboembolic event. Review of the patient’s image study 
revealed that the tumor, with associated thrombus, extended from the liver through the inferior 
vena cava into the right atrium. He refused surgical intervention, received self-paid Sorafenib 
and then underwent 3 cycles of clinical trial. He finally died of progressive disease 8 months 
after diagnosis. Following review of the literature regarding the clinical features, management, 
and outcomes of HCC with heart involvement, we concluded that HCC with heart involvement 
strongly portends a poor prognosis. 
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中文摘要 
  肝細胞癌合併心臟侵犯並不常見，我們報告一肝細胞癌合併右心房侵犯的 58 歲男
性；因為臨床上沒有右心衰竭的症狀，也沒有任何血管栓塞的表現，此右心房的癌細胞
侵犯是於例行的影像追蹤時發現的。由影像檢查可見，癌細胞與其伴隨的栓塞從肝臟經
由下腔靜脈一路侵犯到右心房。該病患拒絕手術的介入，而接受標靶藥物 (Sorafenib) 以
及後續的臨床試驗；然而整個病程持續惡化，病患於診斷後 8 個月死亡。我們進一步回
顧文獻中關於肝細胞癌合併心臟侵犯的臨床表現、治療以及預後；總而言之，肝細胞癌
合併心臟侵犯的病患預後極差。 
 
關鍵字: 肝細胞癌、心臟侵犯、腫瘤栓塞 
INTRODUCTION 
Hepatocellular carcinoma (HCC) with heart in-
volvement is an infrequently occurring condition [1], 
and is usually associated with poor patient prognosis 
[2,3]. The patient presented to our hospital as ad-
vanced HCC with heart involvement, and we report 
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 this unusual case having made an extensive review of 
the literature. 
 
CASE REPORT 
A 58-year-old male presented with a body weight 
loss of 9 kilograms in the last 2 months, also com-
plaining of tea-colored urine. He went to a local hos-
pital for an initial evaluation on June 20th, 2011, 
whereupon physical examination showed icteric sclera 
and abdominal distention. Serum biochemistry re-
vealed an aspartate aminotransferase (AST) level of 
103 U/L (normal ranges 0-39 U/L), an alanine ami-
notransferase (ALT) level of 118 U/L (normal ranges 
0-54 U/L), high serum level of alpha-fetoprotein (AFP) 
(5631.84 ng/ml), and positive hepatitis B surface an-
tigen. Abdominal echo showed cirrhotic liver and 
multiple hepatic tumors (3.3-4.5 cm) with left portal 
vein thrombosis. He was referred to our hospital for 
further evaluation on July 8th, 2011. 
At our hospital, the patient’s white blood cell 
count was determined to be 5500/μL, hemoglobin was 
12 g/dL, platelet count was 224000/μL, and pro-
thrombin time was 11.7 seconds. Serum biochemistry 
revealed total bilirubin 2.8 mg/dL, albumin 4.2 g/dL, 
and alkaline phosphatase 114 U/L. The patient’s 
Child-Pugh classification was stage A (score 6), and 
serology revealed negative hepatitis B e antigen, posi-
tive hepatitis B e antibody, and positive hepatitis B 
core antibody. The DNA level of hepatitis B virus 
(HBV) was not checked. Abdominal computed to-
mography (CT) showed bilateral hepatic masses with 
the maximal tumor size up to 6 cm (Figure 1). The 
patient was diagnosed with advanced HCC, specifi-
cally American Joint Committee on Cancer (AJCC) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Abdominal computed tomography showed 
bilateral multiple hepatic masses with the 
maximal tumor size up to 6 cm (arrow) at 
diagnosis 
 
 
clinical T3bN0M0, clinical stage IIIB, Barcelona- 
Clinic Liver Cancer (BCLC) stage C, Cancer of the 
Liver Italian Program (CLIP) score 3.  
With a diagnosis of bilateral multiple HCC with 
large tumor sizes and left portal vein thrombosis, nei-
ther surgery, percutaneous ethanol injection, radiofre-
quency ablation, or embolization were feasible. After 
the patient received a thorough explanation of his ex-
isting medical circumstances, he opted for self-paid 
Sorafenib (200 mg/tab, 1-2 tab twice daily) from July 
22nd. He also received Entecavir (0.5 mg/day) for 
HBV-related cirrhosis. However, subsequent follow- 
up abdominal CT showed progressing HCC. Sorafenib 
was discontinued on October 20th, and clinical trial 
therapy after the failure of the first-line Sorafenib 
treatment was considered.  
Abdominal CT in November 2011 demonstrated 
hepatic tumors with direct invasion to the inferior ve-
na cava and the right atrium (Figure 2A), and echo-
cardiography revealed one mass around 2.55 cm2 in 
the area extending from the entry site of inferior vena 
cava to the right atrium (Figure 2B). There were no 
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Figure 2. (A) Abdominal computed tomography 
showed hepatic tumors with direct invasion 
to the inferior vena cava (arrow) and the 
right atrium (arrow head). (B) Echocardi-
ography revealed one mass around 2.55 
cm2 in area located from the entry site of 
inferior vena cava to the right atrium 
 
 
 
 
 
 
 
 
 
 
Figure 3. Echocardiography 1 month later revealed 
progressively enlarged right atrial mass 
 
 
clinical features of right heart failure and thrombo-
embolic events. Although the patient was fully in-
formed about the risks and benefits of surgical inter-
vention, he refused such treatment, and received 3 
cycles of clinical trial (NCT01140347) from Novem-
ber 10th to December 8th. 
Abdominal CT was again performed in December, 
which revealed hepatic tumors progressively increased 
in size and bilateral lung metastasis. Additionally, 
echocardiographic imaging revealed progressively 
enlarged right atrial mass (Figure 3). The patient was 
withdrawn from the clinical trial, and progressive hy-
perbilirubinemia soon developed, whereafter the pa-
tient expired 3 months later. 
 
DISCUSSION 
One postmortem study [1] demonstrated hepatic 
and portal vein invasion in the majority of patients 
with HCC, but heart involvement occurred in less than 
5% of all cases. Such invasion is usually via the he-
patic vein and inferior vena cava. In one report [4], 
most patients with HCC invading to the right atrium 
were asymptomatic (39.5%), with some presenting as 
edema in the legs (37.5%), exertional dyspnea (31.3 
%), chest pain (8.3%), syncope (2.1%), and hypoten-
sion (2.1%), which were constitutional and nonspecif-
ic. In another report [5], the lesions involved in pa-
A 
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 tients with HCC were in the right atrium, the lung 
(12.5%), inferior vena cava (25%), and the left atrium 
(12.5%). 
There were no significant differences in age, se-
rum levels of AFP or percentage of right hepatic lobe 
involvement between those with and without heart 
involvement [2]. Diagnostic methods customarily em-
ployed include transthoracic and transesophageal echo-
cardiography, angiography, computed tomography, 
and radioisotope scintigraphy [2]. 
Management of patients with HCC and heart in-
volvement comprises nonsurgical treatment and sur-
gical intervention. Nonsurgical treatment, including 
thalidomide, radiation and chemotherapy, would im-
prove survival and achieve symptomatic relief [6]. 
The overall response rate of transcatheter arterial 
chemoembolization for advanced HCC with invasion 
into the inferior vena cava and the right atrium was 
53.8%, and the median survival time was 4.2 months 
(1.5-76.7 months) [3]. The median survival time of the 
responders was 13.5 months (1.5-76.7 months), and 
that of the non-responders was 3.3 months (2.1-24.3 
months) [3]. Although aggressive surgical intervention 
would rescue selected patients from life-threatening 
heart failure [7], the survival time following the sur-
gical intervention varied from 1 month to more than 
30 months [5]. The prognostic factors in those with 
heart involvement receiving surgical intervention were 
potential lung metastasis or systemic spread during the 
cardiopulmonary bypass surgery, technique depend-
ence procedure, and baseline hepatic condition [7]. 
Patients without heart involvement had signifi-
cantly longer survival duration than those with heart 
involvement (5.0 ± 2.1 months versus 2.1 ± 1.0 
months) [2]. Patients with HCC and heart involvement 
usually died within a short period because of pulmo-
nary embolism, heart failure, underlying cirrhosis, or 
disease progression [8]. 
This is a case of advanced HCC with direct inva-
sion to the left hepatic vein, inferior vena cava and 
right atrium, all of which contributed to a poor prog-
nosis and challenges in management. Our patient re-
fused surgical intervention after a comprehensive 
medical consultation regarding his options, and there-
after received the clinical trial. Unfortunately, his con-
dition progressed, and he finally died of advanced 
HCC with multiple organ failure 8 months after diag-
nosis. 
In conclusion, HCC with heart involvement is rare 
and typically heralds a terminal condition. Although 
nonsurgical treatment or surgical intervention could 
improve survival, the overall prognosis is very poor. 
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